miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma

Wu,Ying; Yu,Jia; Ma,Yanni; Wang,Fang; Liu,Honggang

doi:10.3892/ol.2016.4707

miR-148a and miR-375 may serve as predictive biomarkers for early diagnosis of laryngeal carcinoma

Authors:
- Ying Wu
- Jia Yu
- Yanni Ma
- Fang Wang
- Honggang Liu
View Affiliations

Affiliations: Department of Pathology, Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China, Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, School of Basic Medicine Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
Published online on: June 13, 2016 https://doi.org/10.3892/ol.2016.4707
Pages: 871-878
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of microRNAs (miRs) as possible biomarkers and therapy targets has been extensively investigated in a number of types of cancer. However, the aberrant expression of miRs in laryngeal squamous cell carcinoma (LSCC), particularly during the progression of the disease, is poorly understood. In the present study, the role of miRs as possible novel early pre‑diagnostic biomarkers of LSCC was investigated. TaqMan probe stem‑loop quantitative polymerase chain reaction was utilized to accurately measure the amount of miR‑148a and miR‑375 in clinical samples of mild dysplasia, moderate dysplasia, severe dysplasia, cancer in situ, laryngeal cancer and normal epithelial controls. The application of miR‑148a and miR‑375 as potential predictive biomarkers for early diagnosis of LSCC was analyzed. The results of the present study suggested that miR‑148a and miR‑375 were significantly upregulated in LSCC tissues, and increased expression of miR‑375 was associated with a more aggressive phenotype of LSCC. Additional investigation revealed that miR‑148a and miR‑375 increased during different dysplasia stages of LSCC carcinogenesis, and high‑level expression of miR‑148a or miR‑375 in patients with laryngeal dysplasia may predict subsequent malignant transformation. miR‑148a and miR‑375 were significantly upregulated during LSCC carcinogenesis and may serve as possible predictive biomarkers for early diagnosis of LSCC.

View Figures

View References

1	Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, Wang C, Liu X and Zhou X: Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. Oral Oncol. 48:686–691. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cai K, Wang Y and Bao X: MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. J Exp Clin Cancer Res. 30:732011. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
4	Fleskens SA, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ, Speel EJ, Kremer B, Takes R and Slootweg P: Interobserver variability of laryngeal mucosal premalignant lesions: A histopathological evaluation. Mod Pathol. 24:892–898. 2011. View Article : Google Scholar : PubMed/NCBI
5	Furusaka T, Susaki Y, Saito T, Katsura Y and Ikeda M: Long-term follow-up and salvage surgery in patients with T2N0M0 squamous cell carcinoma of the glottic larynx following concurrent chemoradiation therapy with cisplatin and 5-fluorouracil for laryngeal preservation. Acta Otolaryngol. 133:91–98. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kimura S, Naganuma S, Susuki D, Hirono Y, Yamaguchi A, Fujieda S, Sano K and Itoh H: Expression of microRNAs in squamous cell carcinoma of human head and neck and theesophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 23:1625–1633. 2010.PubMed/NCBI
7	Xie L, Qian X and Liu B: MicroRNAs: Novel biomarkers for gastrointestinal carcinomas. Mol Cell Biochem. 341:291–299. 2010. View Article : Google Scholar : PubMed/NCBI
8	Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S, Briones J, Natkunam Y, Sehn LH, Gascoyne RD, et al: MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 17:4125–4135. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Borel C, Deutsch S, Letourneau A, Migliavacca E, Montgomery SB, Dimas AS, Vejnar CE, Attar H, Gagnebin M, Gehrig C, et al: Identification of cis- and trans-regulatory variation modulating microRNA expression levels in human fibroblasts. Genome Res. 21:68–73. 2011. View Article : Google Scholar : PubMed/NCBI
11	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J and Chen J: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
13	Davidson B, Tropé CG and Reich R: The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol. 133:640–646. 2014. View Article : Google Scholar : PubMed/NCBI
14	Nugent M: MicroRNA function and dysregulation in bone tumors: The evidence to date. Cancer Manag Res. 6:15–25. 2014. View Article : Google Scholar : PubMed/NCBI
15	Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, Yang K, He X and Chen S: MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol. 53:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Kim S and Kim IM: Regulation of metastasis by microRNAs in ovarian cancer. Front Oncol. 4:1432014. View Article : Google Scholar : PubMed/NCBI
17	Han C, Yu Z, Duan Z and Kan Q: Role of microRNA-1 in human cancer and its therapeutic potentials. Biomed Res Int. 2014:4283712014. View Article : Google Scholar : PubMed/NCBI
18	Yu X, Wu Y, Liu Y, Deng H, Shen Z, Xiao B and Guo J: miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma. Curr Pharm Biotechnol. 15:503–508. 2014. View Article : Google Scholar : PubMed/NCBI
19	Li W, Ma H and Sun J: MicroRNA-34a/c function as tumor suppressors in Hep-2 laryngeal carcinoma cells and may reduce GALNT7 expression. Mol Med Rep. 9:1293–1298. 2014.PubMed/NCBI
20	Yungang W, Xiaoyu L, Pang T, Wenming L and Pan X: miR-370 targeted FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma (LSCC). Biomed Pharmacother. 68:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zhang T, Liu M, Wang C, Lin C, Sun Y and Jin D: Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 31:3859–3863. 2011.PubMed/NCBI
22	Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M and Xiao H: MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 35:5953–5963. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhang HK and Liu HG: Is severe dysplasia the same lesion as carcinoma in situ? 10-year follow-up of laryngeal precancerous lesions. Acta Otolaryngol. 2:325–328. 2012. View Article : Google Scholar
24	Barnes L, Eveson JW, Reichart P and Sidransky D: World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. IARC Press. (Lyon). 10–80. 2001.
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
27	Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol. 8:467–477. 2011. View Article : Google Scholar : PubMed/NCBI
28	Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhu Y, Yang SR, Wang PP, Savas S, Wish T, Zhao J, Green R, Woods M, Sun Z, Roebothan B, et al: Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: Overall and by tumour molecular phenotype. Br J Cancer. 110:1359–1366. 2014. View Article : Google Scholar : PubMed/NCBI
30	Nan H, Giovannucci EL, Wu K, Selhub J, Paul L, Rosner B, Fuchs CS and Cho E: Pre-diagnostic leukocyte genomic DNA methylation and the risk of colorectal cancer in women. PLoS One. 8:e594552013. View Article : Google Scholar : PubMed/NCBI
31	Liu L, Ye JX, Qin YZ, Chen QH and Ge LY: Evaluation of miR-29c, miR-124, miR-135a and miR-148a in predicting lymph node metastasis and tumor stage of gastric cancer. Int J Clin Exp Med. 8:22227–22236. 2015.PubMed/NCBI
32	Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep. 35:1425–1432. 2016.PubMed/NCBI
33	Ma L, Xu Z, Xu C and Jiang X: MicroRNA-148a represents an independent prognostic marker in bladder cancer. Tumour Biol. Dec 23–2015.[Epub ahead of print].
34	Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Beretta L: Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology. 63:864–879. 2016. View Article : Google Scholar : PubMed/NCBI
35	Wu T, Qu L, He G, Tian L, Li L, Zhou H, Jin Q, Ren J, Wang Y, Wang J, et al: Regulation of laryngeal squamous cell cancer progression by the lncRNA H19/miR-148a-3p/DNMT1 axis. Oncotarget. 7:11553–11566. 2016.PubMed/NCBI
36	Wu Y, Wang X, Wu F, Huang R, Xue F, Liang G, Tao M, Cai P and Huang Y: Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One. 7:e410012012. View Article : Google Scholar : PubMed/NCBI
37	Clare SE, Pardo I, Mathieson T, Lillemoe HA, Blosser RJ, Choi M, Sauder CAM, Doxey DK, Badve S, Storniolo AMV, et al: Abstract P1-03-02: ‘Normal’ tissue adjacent to breast cancer is not normal. Cancer Res. 72:P103–02. 2012. View Article : Google Scholar